GSM城市站国家站国际

JAMA CATCH 试验 1706 人、40 家诊所:单片复方降压药 18 个月收缩压降 19.1 对 9.0 毫米汞柱,达标率 69.5% 对 29.2%

2026-11-15 · 医疗 · GSM News
JAMA CATCH 试验 1706 人、40 家诊所:单片复方降压药 18 个月收缩压降 19.1 对 9.0 毫米汞柱,达标率 69.5% 对 29.2%

《美国医学会杂志》(JAMA)2026 年 11 月 8 日发表 CATCH 随机临床试验结果,并于美国心脏协会科学年会迟发科学环节同步报告:把多种降压药合为一片的单片复方方案,配合团队照护,在哥伦比亚与牙买加 40 家基层诊所的 1706 名未控制高血压患者中,降压效果优于多片药的常规治疗。试验由德克萨斯大学西南医学中心研究者与哥伦比亚、牙买加同事共同领衔,历时四年招募与随访。

18 个月时,单片复方组收缩压平均下降 19.1 毫米汞柱,常规治疗组下降 9.0 毫米汞柱。达到试验目标(收缩压低于 130 毫米汞柱且舒张压低于 80 毫米汞柱)的比例,单片组为 69.5%,标准治疗组为 29.2%。严重不良事件发生率两组分别为 7.9% 与 9.9%。复方单片含缬沙坦、氨氯地平,需要时加氢氯噻嗪两至三种成分。

试验结束后 6 个月,干预组仍有 75% 的患者继续接受由医保或政府项目覆盖的单片复方治疗,并维持较好的血压控制,研究者据此认为该策略具有可持续性。研究由美国国立卫生研究院下属国家心肺血液研究所资助(UG3/UH3 HL152373)。

报道同时注明试验局限:研究为开放标签设计(患者与医生知道分组),且仅在两个国家开展,结果在其他人群与医疗体系中仍需验证;干预是单片药物与团队支持(培训、健康辅导、家庭监测与反馈)的组合,试验不能把药片本身的贡献与配套支持完全分开。本稿只报道试验事实,不作个体用药建议。

图中是医务人员使用血压计为受检者测量血压。

JAMA CATCH Trial: Single-Pill Combination Controlled Blood Pressure in 69.5% vs 29.2% of 1,706 Patients

Results of the CATCH randomized clinical trial, published in JAMA on November 8, 2026, and presented in the Late-Breaking Science sessions of the American Heart Association Scientific Sessions, show that combining antihypertensive medicines into a single pill, delivered with team-based care, lowered blood pressure more effectively than usual multi-pill treatment. The trial enrolled 1,706 patients with uncontrolled hypertension at 40 primary care clinics in Colombia and Jamaica and was co-led by UT Southwestern Medical Center researchers with colleagues in Colombia, Jamaica, and the United States over four years.

After 18 months, systolic blood pressure fell by 19.1 mm Hg in the single-pill group versus 9.0 mm Hg with usual care. The share reaching the trial goal — systolic below 130 mm Hg and diastolic below 80 mm Hg — was 69.5% with the single-pill combination versus 29.2% with standard care. Serious adverse events occurred in 7.9% versus 9.9% of patients, respectively. The single pill combined two or three agents: valsartan, amlodipine, and, if needed, hydrochlorothiazide.

Six months after the trial ended, 75% of patients in the intervention group were still receiving single-pill combination treatment covered by health insurance or government programs and maintained better blood pressure control, which the researchers describe as evidence the strategy is sustainable. The study was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health (UG3/UH3 HL152373).

Reported limitations include the open-label design, in which patients and clinicians knew the treatment assignment, and conduct in only two countries, so confirmation elsewhere is still needed; the intervention also combined the pill with team support, training, coaching, home monitoring, and audit, so the trial cannot separate the pill's effect from the support around it. This report presents trial facts only and makes no individual medication recommendation.

来源:美国医学会杂志

发布:GSM·美国(发布链接)

图片来源:图中是医务人员使用血压计为受检者测量血压。U.S. Marine Corps photo by Cpl. Jesse K. Alwin, via Wikimedia Commons

GSM Global · 本篇英文版 English edition of this story

本频道最新更多 ›

← 返回医疗 全部新闻 关于我们

GSM首页白宫联邦加州南加各州社会军事司法选举世界中国城市站国家站移民宣传专题视频直播放映厅电子书电子报科技金融教育医疗影视音乐体育文旅时尚演出活动娱乐游戏生活美食户外交通汽车地产保险儿童长者留学生宠物信仰非盈利机构